cagkansayin/iStock via Getty Images Roche Holding (OTCQX:RHHBY) announced positive topline results from the phase 1b trial of its obesity candidate CT-388 this week and its share price received a 4% boost on the day of the announcement. The results look strong with 18.8% placebo-adjusted weight loss at week 24, but they also leave a lot to be desired in terms of very valuable information, especially on the side of safety and tolerability, and we have to wait for the full data presentation at a medical confe ...